左炔诺孕酮宫内缓释系统用于子宫内膜异位症保守性手术后复发的治疗

目的 探讨左炔诺孕酮宫内缓释系统(LNG-IUS)用于子宫内膜异位症(内异症)患者保守性手术或保守性手术联合药物巩固治疗后复发者治疗的效果.方法 选择因内异症复发而就诊的患者23例,于月经周期第5～7天宫内放置LNG-IUS.所有患者均无生育要求且不愿再次手术.于放置LNG-IUS后3、6、12、24、36个月随访,观察放置LNG-IUS前后患者疼痛视觉模拟(VAS)评分、血清CA125水平、卵巢内异症囊肿体积的变化以及月经情况、体质量等指标.结果 (1)VAS评分:放置LNG-IUS后12个月,痛经、慢性盆腔痛或性交痛缓解最为明显,VAS评分由放置LNG-IUS前的(5.9±2.3)、(4.3±2.0)分下降为(1.0±0.7)、(1.4±1.1)分,分别比较,差异均有统计学意义(P＜0.01).(2)囊肿体积:11例患者复发表现为卵巢内异症囊肿,放置LNG-IUS后6个月,卵巢内异症囊肿体积由放置前的(11.4±6.1)cm3下降至(5.5±3.4)cm3,两者比较,差异也有统计学意义(P＜0.01);放置12个月时,2例卵巢内异症囊肿消失,放置24个月时,共9例卵巢内异症囊肿消失.(3)血清CA125:从放置LNG-IUS后6个月时开始,CA125水平显著下降,由放置前的(65.5±19.6)kU/L降至放置6个月时的(42.1±13.6)kU/L,差异有统计学意义(P＜0.01),放置后12个月时,CA125水平仍继续下降,此后趋于平稳.(4)其他:放置LNG-IUS后6个月内,阴道不规则出血或点滴出血是常见现象,随着放置时间延长,情况明显缓解.少数患者出现体质量增加的情况.结论 内异症保守性手术或手术联合药物巩固治疗后复发的患者,应用LNG-IUS可有效地缓解疼痛症状,降低血清CA125水平,缩小卵巢内异症囊肿体积,是一种有效、安全、持续时间长、全身副作用少、依从性高的治疗方法.

Abstract：

Objective To evaluate the efficiency of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment. Methods Twenty-three patients with recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment were treated by LNG-IUS. All patients rejected further operation and had no desire of fertility. The visual analogue scale (VAS) scores of pain, menstrual model, weight and serum CA125 level and the volume of ovarian endometriotic cysts before and after 3, 6, 12, 24 and 36 months of treatment were recorded and compared. Results ( 1 ) VAS score:after 12 months of using LNG-IUS, dysmenorrheal, chronic pelvic pain or dyspareunia were relieved significantly. VAS score were dropped from 5.9 ± 2. 3,4. 3 ± 2.0 to 1.0 ± 0. 7,1.4 ± 1. 1 ( P ＜ 0. 01 ). ( 2 )Volum of cysts :after 6 months of using LNG-IUS, the volume of recurrent ovarian endometriotic cysts in 11 patients were reduced from ( 11.4 ± 6. 1 ) em3 to ( 5. 5 ± 3.4 ) em3 significantly ( P ＜ 0. 01 ). At 12 months of follow-up, it suggested that 2 patients' ovarian endometriotic cysts disappeared. At 24 months follow-up,9 patients ovarian endometriotic cysts disappeared ( 3 ) CA125: serum CA125 decreased from ( 65.5 ± 19. 6 )kU/L to (42. 1 ± 13.6) kU/L at 6 months after treatment remarkably (P ＜ 0. 01 ). Continued to decrease after 12 months and then become steady. Irregular bleeding and spotting was the main side effects, weight gain was also observed in few patients. Conclusions LNG-IUS could be used in treatment of recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment effectively. It could relieve pain, reduce the level of CA125 and decrease the size of ovarian endometriotic cysts. LNG-IUS seems to be an effective, safe, and long term treatment for endometriosis with fewer side effects and better compliance.

Evaluation of levonorgestrel-releasing intrauterine system in treatment of recurrent endometriosis after conservative surgery

Objective To evaluate the efficiency of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment. Methods Twenty-three patients with recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment were treated by LNG-IUS. All patients rejected further operation and had no desire of fertility. The visual analogue scale (VAS) scores of pain, menstrual model, weight and serum CA125 level and the volume of ovarian endometriotic cysts before and after 3, 6, 12, 24 and 36 months of treatment were recorded and compared. Results ( 1 ) VAS score:after 12 months of using LNG-IUS, dysmenorrheal, chronic pelvic pain or dyspareunia were relieved significantly. VAS score were dropped from 5.9 ± 2. 3,4. 3 ± 2.0 to 1.0 ± 0. 7,1.4 ± 1. 1 ( P ＜ 0. 01 ). ( 2 )Volum of cysts :after 6 months of using LNG-IUS, the volume of recurrent ovarian endometriotic cysts in 11 patients were reduced from ( 11.4 ± 6. 1 ) em3 to ( 5. 5 ± 3.4 ) em3 significantly ( P ＜ 0. 01 ). At 12 months of follow-up, it suggested that 2 patients' ovarian endometriotic cysts disappeared. At 24 months follow-up,9 patients ovarian endometriotic cysts disappeared ( 3 ) CA125: serum CA125 decreased from ( 65.5 ± 19. 6 )kU/L to (42. 1 ± 13.6) kU/L at 6 months after treatment remarkably (P ＜ 0. 01 ). Continued to decrease after 12 months and then become steady. Irregular bleeding and spotting was the main side effects, weight gain was also observed in few patients. Conclusions LNG-IUS could be used in treatment of recurrent endometriosis after conservative surgery or conservative surgery combined with medical treatment effectively. It could relieve pain, reduce the level of CA125 and decrease the size of ovarian endometriotic cysts. LNG-IUS seems to be an effective, safe, and long term treatment for endometriosis with fewer side effects and better compliance.